Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Additional Data Required on Alogliptin + Actos FDC as Well: Takeda
September 14, 2009
- DSP to Acquire Sepracor at US$2.6 Bil.
September 14, 2009
- REGULATORY NEWS IN BRIEF
September 14, 2009
- Hisamitsu Completes Acquisition of Noven Pharm.
September 14, 2009
- Unike, Houken Develop Generics Use Promotion Report System
September 14, 2009
- Janssen Enhances CNS Field with 370 MRs
September 14, 2009
- Pharmacists Should Be Allowed to Change Specifications/Dosage Forms at Their Own Discretion
September 14, 2009
- China's Essential Drug List May Hit Non-Chinese Drug Firms Operating in China
September 14, 2009
- JPA Member Pharmacies Continue to Sell OTC Drugs by Phone: Kenko.com
September 14, 2009
- Yano Research Predicts 6-9% NHI Price Cuts in April 2010
September 14, 2009
- Need for Importing New-Type Flu Vaccines Questioned
September 14, 2009
- Blopress Ranked as Best-Selling Drug in Japan in 1st Qtr: IMS Japan
September 14, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 14, 2009
- Market for RA Drugs to Expand to ¥195 Bil. in 2016: Fuji-Keizai
September 14, 2009
- National Healthcare Expenditure Reaches Highest-Ever ¥34,136 Bil. in FY2007
September 14, 2009
- Drug Sales & Marketing System Needs "Systematic Throwback": Mr Kadonaga
September 14, 2009
- Survey Shows Large Regional Gaps in Respiratory Medical Services
September 14, 2009
- BUSINESS NEWS IN BRIEF
September 14, 2009
- Nearly 70% of Local Gov't-Managed Hospitals Operate in the Red
September 14, 2009
- Novartis Ranked No. 1 in Oncology: Cancer Patient Survey
September 14, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…